NSCLC | MediPaper Medical Communications Ltd.

Posts

Sotorasib for the treatment of KRASG12C mutated lung cancer

15th October 2020/0 Comments/in Gastrointestinal Cancer, Lung Cancer, Oncology, Targeted Therapies /by Kirsty LEE

RAS is the most frequently mutated gene family in cancers, with KRAS mutations being involved as a driver in three of the most lethal cancers – lung cancer, colorectal cancer, and pancreatic cancer. Incidence of KRAS mutations vary between ethnicity with Caucasians having a higher incidence than African-Americans or Asians. In non-small lung cancer (NSCLC), the most common KRAS mutation is G12C. In Asia, G12C mutations in particular account for 14.5% of KRAS mutations in the Chinese population. KRAS G12C was identified in 4.3% of lung cancer samples and 2.5% of colorectal cancer samples.

apmatinib-therapy-for-the-treatment-of-MET-positive-non-small-cell-lung-cancer

Capmatinib therapy for the treatment of MET-positive non-small cell lung cancer

15th October 2020/0 Comments/in Lung Cancer, Oncology, Targeted Therapies /by Kirsty LEE

A number of tyrosine kinase inhibitors (TKIs) are now available for the treatment of various types of non-small cell lung cancers (NSCLC), including epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-rearranged NSCLC. However, amplification of the MET gene, which codes for the hepatocyte growth factor receptor (HGFR), has been found to be one of the most prominent mechanisms of secondary resistance to EGFR TKIs. Similarly, the MET exon 14 (METex14) mutation has also emerged as a potential tumour driver due to its role in cancer proliferation, and thus also a promising target for NSCLC.

apmatinib-therapy-for-the-treatment-of-MET-positive-non-small-cell-lung-cancer

Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

Selpercatinib displays efficacy in RET fusion-positive non-small cell lung cancer

7th September 2020/0 Comments/in Chemotherapy, Lung Cancer, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals /by Kirsty LEE

Aberrant RET activation has shown to be a clinical driver of tumour growth and proliferation. It is reported that 1-2% of non-small cell lung cancer patients have activating RET fusions. Clinical characteristics of these patients are generally younger (<60 years) with minimal or no smoking history, and frequent presentation with brain metastases at diagnosis of advanced disease. RET mutations are mutually exclusive with other common lung cancer genetic abberations, such as reported for KRAS, EGFR, and ALK.

Selpercatinib-displays-efficacy-in-RET -fusion-positive-non-small-cell-lung-cancer

ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

ASCO 2020 Lung, Breast, and Liver Cancer Update

30th June 2020/0 Comments/in ASCO 2020 Annual Meeting, Breast Cancer, Chemotherapy, China, Conferences, Endocrine Therapy, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Targeted Therapies /by Kirsty LEE

This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.

ASCO 2020 ASCO20 virtual meeting NSCLC SCLC lung cancer breast cancer hepatocellular cancer HCC colorectal cancer CRC

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 05-Jun-2020

5th June 2020/19 Comments/in AE Management, Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, ImmunoOncology, Immunotherapy, irAE Management, Lung Cancer, Melanoma & Skin Cancer, Oncology /by News Feed

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised

12th June 2019/0 Comments/in ASCO 2019 Annual Meeting, Chemotherapy, Conferences, Immunotherapy, Lung Cancer, Oncology, Radiology, Surgery, Targeted Therapies, Translational Research /by Stijn van den Borne, MSc

Non-small cell lung cancer (NSCLC) was a key feature of the American Society of Clinical Oncology (ASCO) 2019 annual meeting. This year, exciting results with neoadjuvant immunotherapy (I-O) from the LCMC3, NEOSTAR, and GECP16/03_NADIM studies as well as combinations of I-O and PARP-inhibitors with chemoradiation therapy, and more. A summary of 36 oral presentations on NSCLC, SCLC, and Mesothelioma.

ASCO 2019 lung cancer NSCLC ASCO19 SCLC mesothelioma KEYNOTE-189 KEYNOTE-001 IMpower150 MYSTIC LCMC3 Lung-MAP S1400G S1400I Flaura CALGB 30901 DETERRED COMPASS

Single-agent pembrolizumab FDA approved for the first-line treatment of stage III NSCLC with PD-L1 TPS ≥1%

18th April 2019/0 Comments/in US FDA Onc\Haem Approvals /by News Feed

On 11 April 2019, the FDA approved single-agent pembrolizumab (Keytruda®, Merck) for the first-line treatment of stage III/IV non-small cell lung cancer (NSCLC) patients with a PD-L1 Tumor Proportion Score (TPS) ≥1% who are not amenable to surgical resection or definitive chemoradiation and who have no known EGFR or ALK genomic aberrations.

Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

23rd March 2019/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On 18 March 2019, the FDA approved atezolizumab (Tecentriq®, Genentech) plus carboplatin and etoposide as front-line treatment of adult extensive-stage small cell lung cancer (ES-SCLC) patients.

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

11th December 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals /by News Feed

On 6 December 2018, the FDA approved atezolizumab (Tecentriq®, Roche/Genentech) plus bevacizumab and chemotherapy with paclitaxel and carboplatin for the frontline treatment of metastatic non-squamous non-small cell lung cancer (NSq NSCLC) patients not harbouring any EGFR or ALK genomic tumour aberrations.

Lorlatinib FDA approved for metastatic ALK-positive NSCLC

6th November 2018/0 Comments/in Lung Cancer, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals /by News Feed

On November 2nd 2018, lorlatinib (LORBRENA®, Pfizer) received accelerated approval by the FDA for the second- and third-line treatment of patients with metastatic, anaplastic lymphoma kinase (ALK)-positive, non-small cell lung cancer (NSCLC). Third-line patients should have had progression on crizotinib and another ALK-inhibitor for metastatic disease, and second-line patients should have had progression on either alectinib or ceritinib in the first-line for metastatic disease.

Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

1st November 2018/1 Comment/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On October 30th 2018, the FDA approved the use of programmed death 1 (PD-1) inhibitor pembrolizumab (Keytruda®, Merck) in combination with carboplatin plus paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Pembrolizumab plus chemotherapy effective in squamous NSCLC

Pembrolizumab plus chemotherapy effective in squamous NSCLC

8th October 2018/2 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by News Feed

Pembrolizumab (Keytruda®, Merck) in combination with chemotherapy was associated with longer overall survival (OS) and progression-free survival (PFS) when compared to placebo plus chemotherapy in patients with untreated metastatic squamous cell non-small cell lung cancer (NSCLC).

Pembrolizumab plus chemotherapy effective in squamous NSCLC

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

5th October 2018/0 Comments/in Lung Cancer, Oncology, Targeted Therapies /by News Feed

Brigatinib (Alunbrig®, Ariad) significantly prolongs the progression-free survival (PFS) in anaplastic lymphoma kinase (ALK) inhibitor-naïve patients with ALK-rearranged non-small cell lung cancer (NSCLC) when compared to crizotinib, as resulted from the ALTA-1L study.

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

2nd October 2018/0 Comments/in ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, WCLC 2018 /by News Feed

Avelumab (Bavencio®, Merck KGaA) does not improve the overall survival (OS) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-doublet chemotherapy, as resulted from the JAVELIN Lung 200 study (NCT02395172). The safety profile favoured avelumab over docetaxel.

JAVELIN Lung 200 avelumab vs docetaxel in patients with pretreated advanced non-small cell lung cancer NSCLC

Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

28th September 2018/0 Comments/in Lung Cancer, Targeted Therapies, US FDA Onc\Haem Approvals /by News Feed

On September 27, 2018, the FDA approved dacomitinib (Vizimpro®, Pfizer) as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R mutations as confirmed by an FDA-approved test.

Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

25th September 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, WCLC 2018 /by News Feed

An interim analysis of the Phase III IMpower132 study showed that atezolizumab (Tecentriq®, Roche/Genentech) plus platinum-based chemotherapy (cisplatin or carboplatin) with pemetrexed improves the median progression-free survival (PFS) in treatment-naïve patients with non-squamous non-small cell lung cancer (NSCLC). The median PFS for atezolizumab plus pemetrexed and a platinum salt was 7.6 months vs 5.2 months with chemotherapy alone (HR=0.60, 95% CI: 0.49-0.72; p<0.0001).

Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

24th September 2018/0 Comments/in Lung Cancer, Oncology, Targeted Therapies /by Stijn van den Borne, MSc

First-line osimertinib was associated with a clinically meaningful progression-free survival (PFS) improvement when compared to a standard-of-care (SOC) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in a sub-analysis of Asian patients who participated in the FLAURA trial (NCT02296125).

First-line osimertinib vs EGFR-TKI in Asian patients with advanced NSCLC

Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作醫學作家香港

© Eraxion / 123RF Stock Photo

Capmatinib plus gefitinib promising in MET-dysregulated NSCLC

11th September 2018/0 Comments/in China, Lung Cancer, Oncology, Targeted Therapies /by News Feed

The combination capmatinib (INC280, Novartis) plus gefitinib (Iressa®, AstraZeneca) showed promising, early phase efficacy in patients with mesenchymal-epithelial transition factor (MET)-dysregulated and epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Lung Cancer Capmatinib plus gefitinib promising in MET-dysregulated NSCLC MediPaper Medical Communications Medical Writer Hong Kong 醫學寫作醫學作家香港

Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

Plasma TMB predicts response to atezolizumab in NSCLC patients

31st August 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Pathology, Translational Research /by News Feed

A high tumour mutational burden in the plasma (bTMB) is a clinically actionable biomarker for atezolizumab (Tencentriq®, Roche) treatment in patients who failed 1st-line platinum-based therapy for advanced non-small cell lung cancer (NSCLC).

Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

© luchschen / 123RF Stock Photo

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22nd August 2018/0 Comments/in Breast Cancer, Genitourinary Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Medical News Asia, Melanoma & Skin Cancer, Oncology, Translational Research /by News Feed

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Pembrolizumab plus pemetrexed-platinum FDA approved for first-line treatment of metastatic non-squamous NSCLC

21st August 2018/2 Comments/in ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, US FDA Onc\Haem Approvals /by News Feed

On 20th of August 2018, the FDA granted regular approval for pembrolizumab (Keytruda®, Merck) plus pemetrexed and a platinum salt in the first-line treatment of patients with metastatic, non-squamous non-small cell lung cancer (NSCLC), not harbouring any EGFR or ALK genomic tumour aberrations.

Pembrolizumab plus pemetrexed-platinum approved for use in the 1st-line treatment of metastatic non-squamous NSCLC

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

©Alex011973 / 123RF Stock Photo

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

13th August 2018/0 Comments/in China, Lung Cancer, Medical News Asia, Oncology, Targeted Therapies /by News Feed

HONG KONG, CHINA – 13 August 2018 – Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), announced that its innovative in-house developed oncology drug pirotinib has commenced into Phase II Clinical testing in China following the completion of a Phase I clinical trial in three renowned cancer research centres in the United States.

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3

© srr283/123RF

Osimertinib in patients with T790M-positive advanced non-small cell lung cancer and brain metastases (AURA3)

30th July 2018/0 Comments/in Chemotherapy, Lung Cancer, Oncology, Targeted Therapies, Translational Research /by News Feed

Osimertinib is active in the second-line treatment of patients with T790M-positive advanced non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, as reported by the investigators of the Phase III AURA3 study.

T790M osimertinib nsclc brain metastasis CNS metastases Osimertinib in patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer and brain metastases AURA3

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

10th May 2018/4 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Hywards / 123RF Stock Photo

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

21st April 2018/6 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

AACR 2018: First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).

AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

19th April 2018/1 Comment/in Lung Cancer, Oncology, Targeted Therapies, Translational Research, US FDA Onc\Haem Approvals /by News Feed

edit+xClone Element

FDA approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Ribociclib FDA label updated to include pre- and perimenopausal women

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

19th April 2018/4 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

AACR 2018: Frontline pembrolizumab plus chemotherapy in NSCLC reduces the risk of death by more than 50%. The Phase III KEYNOTE-189 trial combined pembrolizumab (Keytruda®) plus standard of care platinum-based chemotherapy in non-squamous non–small cell lung cancer (NSCLC) without EGFR or ALK genetic aberrations (NCT0278680)

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

10th April 2018/1 Comment/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

4th April 2018/1 Comment/in China, Lung Cancer, Oncology, Targeted Therapies /by Stijn van den Borne, MSc

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months – not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.

Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

FDA approved durvalumab as maintenace for unresectable stage III NSCLC responding to platinum-based chemoradiation therapy

16th February 2018/0 Comments/in US FDA Onc\Haem Approvals /by News Feed

FDA approved durvalumab (Imfinzi, AstraZeneca Inc.) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. More Information.

©aquir / 123RF Stock Photo

FDA approved a broadened indication of afatinib in the 1st-line treatment of metastatic NSCLC with non-resistant EGFR mutations

12th January 2018/0 Comments/in US FDA Onc\Haem Approvals /by News Feed

FDA granted approval to afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. More Information.

Therapeutic Areas

MediPaper Medical Communications Agency Hong Kong Blog